DOI: https://doi.org/10.22141/2308-2097.53.2.2019.168980

Quantitative analysis of the rate of the antisecretory effect of combined proton pump inhibitor Ezolong

Yu.M. Stepanov, А.V. Salenko

Abstract


Background. The treatment of acid-related diseases is an urgent problem of modern gastroenterology and is due to the wide spread of this group of nosologies in the structure of gastrointestinal pathology. Proton pump inhibitors play the leading role in the treatment of these diseases. The criteria for their choice is the time of onset of action, severity and duration of acid suppression, the stability of the effect during the day, the presence of different dosages of the drug. That is why, in recent years, preference is given to combined drugs. Now in Ukraine, a newer generation of combined drugs is used, one of them is Ezolong. This drug, which, in addition to high-quality esomeprazole (at a dosage of 20 or 40 mg), contains another active ingredient — an antacid in the form of sodium hydrocarbonate (1080 mg). It is this combination that makes this drug unique. The purpose of the study was to determine the speed of the effect of the combined drug Ezolong (esomeprazole 40 mg + sodium hydrocarbonate 1080 mg) on the state of gastric acid production and degree of its inhibition when using a single dose of the drug. Materials and methods. Twenty patients with various forms of chronic gastroduodenitis were taken under observation. The level of acid production was assessed using intragastric pH monitoring with AG-1 acidograph. Next, patients received a single dose of Ezolong (40 mg) and were under observation for 3 hours. Results. Analyzing the rate of antisecretory effect of a single dose of Ezolong, we found that in 95 % of patients this drug leads to an increase in intragastric pH to hypoacidic numbers (from 3.0 to 7.8), in some patients even anacidic pH values are observed. It is proved that Ezolong is characterized by a rapid onset of action (on average 6 minutes) and a significant increase in pH to severe hypoacidity. Conclusions. Ezolong administration provides active, powerful and long-lasting suppression of gastric acid production, it is effective and safe for the treatment of acid-related diseases.


Keywords


acid-related diseases; gastric acid production; treatment; Ezolong; pH monitoring

References


Tkach SM. Differential use of proton pump inhibitors in acid-related pathology. Gastroenterologija, gepatologija, koloproktologija. Zdorovʼja Ukrai'ny. 2016;(3):6-17. (in Russian).

Hagymási K, Müllner K, Herszényi L, Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2011 Jun;12(6):873-88. doi: 10.2217/pgs.11.4.

Mori H, Suzuki H. Role of Acid Suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil. 2019 Jan 31;25(1):6-14. doi: 10.5056/jnm18139.

Mermelstein J, Chait Mermelstein A, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exp Gastroenterol. 2018 Mar 21;11:119-134. doi: 10.2147/CEG.S121056.

Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013 Jan;19(1):25-35. doi: 10.5056/jnm.2013.19.1.25.

Stepanov YuM, Budzak IYa. Maastricht consensus-5: analytical review of statements. Gastroenterologìa. 2017;51(1):36-44. doi: 10.22141/2308-2097.51.1.2017.97870. (in Russian).

Tkach SM. Existing and promising ways to increase the effectiveness of antisecretory therapy in gastroesophageal reflux disease. Zdorovʼja Ukrai'ny. 2013;(320):54-55. (in Russian).

Banerjee S, Weideman RA, Weideman MW, et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol. 2011 Mar 15;107(6):871-8. doi: 10.1016/j.amjcard.2010.10.073.

Ivashkin VT, Mayev IV, Trukhmanov AS, Rumyantseva DE. Modern achievements in the diagnosis and treatment of the refractory gastroesophageal reflux disease. Terapevticheskiy arkhiv. 2018;90(8):4-12. (in Russian).

Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol. 2012 Feb;46(2):93-114. doi: 10.1097/MCG.0b013e3182333820.

Serrano D, Torrado S, Torrado-Santiago S, Gisbert JP. The influence of CYP2C19 Genetic polymorphism on the Pharmacokinetics. Curr Drug Metab. 2012 Nov;13(9):1303-12. doi: 10.2174/138920012803341393.

Chaudhry AS, Kochhar R, Kohli KK. Genetic polymorphism of CYP2C19 and therapeutic response to proton pump inhibitors. Indian J Med Res. 2008 Jun;127(6):521-30.

Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease. Gastroenterology. 2008 Oct;135(4):1383-1391, 1391.e1-5. doi: 10.1053/j.gastro.2008.08.045.

Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006 Dec;4(12):1452-8. doi: 10.1016/j.cgh.2006.09.013.

Yevsyutina YuV, Trukhmanov AS. New opinion on the issue of proton pump inhibitor-refractory gastroesophageal reflux disease. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2014;24(5):4-12. (in Russian).




Copyright (c) 2019 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта